11月 2025
- 首頁
- Immatics
11月 2025Immatics的市場佔有率分析
Prof. Dr. med. Dirk Busch joined Immatics Scientific Advisory Board in 2021. Dirk Busch studied human medicine at the Universities of Mainz and Freiburg, and completed his doctor’s degree in medicine in 1993. Dirk Busch studied human medicine at the Universities of Mainz and Freiburg, and completed his doctor’s degree in medicine in 1993. This was followed by his residency and postdotoral studies at the Children’s Hospital of the University of Würzburg from 1994 until 1996 and at the Section of Infectious Diseases and Immunobiology at the Yale University in New Haven/USA from 1996 until 1999. From there he joined the Technical University of Munich (TUM) where he finished in 2005 his clinical specialization in Medical Microbiology and Infection Epidemiology, and started his own independent research work as principal investigator. He gained his habilitation from TUM in 2001. From 2004 until 2008 he was C3-Professor for Medical Microbiology and Immunology […]
Immatics(包含公司地區)
查看更多網站流量與參與度資訊- immatics.com
Immatics截至 11月 2025 的總收入為 50M - 75M
Immatics 熱門網域產生的總收入
Immatics 熱門網域 3 年內的總收入
Immatics 熱門網域的總收入
Immatics的熱門網域總造訪量
了解Immatics市場觸達率與潛在市場影響力。
過去 3 個月的訪問總量
子公司細目
Immatics的熱門網域平均造訪時長
分析Immatics參與度指標。
過去 3 個月平均造訪時長
子公司細目
Immatics的熱門網域平均頁面瀏覽量
了解Immatics如何保持使用者的參與度、培養其興趣,並鼓勵他們採取下一步。
過去 3 個月平均頁面瀏覽量
子公司細目
想要取得更深入的流量洞見?
篩選超過 2,030 萬家線上企業。在流量激增、開始或停止使用技術或獲得正面評價時,發現新的潛在客戶。
新聞與訊號來自Immatics
透過 Similarweb 銷售訊號提醒,每當目標受眾出現新的機會或威脅時,你就會收到每日更新的已識別購買訊號。
新聞Immatics Biotechnologies GmbH hired Amie Krause as Chief Human Resources Officer on Oct 27th '25.Amie Krause joins Immatics from Dompé, where she served as Chief Human Resources Officer.
10月 27, 2025閱讀更多
新聞Immatics Biotechnologies GmbH hired Venkat Ramanan as Chief Financial Officer on Oct 1st '25.Houston, Texas and Tuebingen, Germany, October 1, 2025 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Venkat Ramanan, Ph.D., as Chief Financial Officer ("CFO"), effective immediately.
10月 1, 2025閱讀更多
新聞Immatics Biotechnologies GmbH launches IMA203 TCR T-cell Therapy data at 2025 ASCO Annual Meeting.Immatics (NASDAQ: IMTX) has announced upcoming presentations of its IMA203 TCR T-cell therapy at the 2025 ASCO Annual Meeting in Chicago.
4月 23, 2025閱讀更多
查看所有Immatics信號
讓銷售團隊專注於最有希望的機會。透過安排機會的優先順序,並在正確的時間參與,您可將工作最佳化,並完成更多交易。